HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
548
548
630
837
426
356
Revenue Growth (YoY)
-13%
-13%
-25%
96%
20%
56.99%
Cost of Revenue
336
336
348
384
311
258
Gross Profit
212
212
281
453
115
97
Selling, General & Admin
103
103
112
133
136
127
Research & Development
148
148
212
302
386
299
Operating Expenses
251
251
325
435
522
426
Other Non Operating Income (Expenses)
60
6
5
1
-11
-10
Pretax Income
521
521
45
105
-360
-155
Income Tax Expense
63
63
7
4
0
11
Net Income
456
456
37
100
-360
-194
Net Income Growth
1,132%
1,132%
-63%
-128%
86%
55%
Shares Outstanding (Diluted)
873.21
872.89
872.82
869.19
847.14
792.68
Shares Change (YoY)
0%
0%
0%
3%
7%
14%
EPS (Diluted)
0.52
0.52
0.04
0.11
-0.42
-0.24
EPS Growth
1,112%
1,112%
-63%
-127%
73%
36%
Free Cash Flow
-88
-88
-17
186
-305
-220
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
38.68%
38.68%
44.6%
54.12%
26.99%
27.24%
Operating Margin
-7.11%
-7.11%
-6.82%
2.15%
-95.53%
-92.13%
Profit Margin
83.21%
83.21%
5.87%
11.94%
-84.5%
-54.49%
Free Cash Flow Margin
-16.05%
-16.05%
-2.69%
22.22%
-71.59%
-61.79%
EBITDA
-26
-26
-31
26
-399
-321
EBITDA Margin
-4.74%
-4.74%
-4.92%
3.1%
-93.66%
-90.16%
D&A For EBITDA
13
13
12
8
8
7
EBIT
-39
-39
-43
18
-407
-328
EBIT Margin
-7.11%
-7.11%
-6.82%
2.15%
-95.53%
-92.13%
Effective Tax Rate
12.09%
12.09%
15.55%
3.8%
0%
-7.09%
Follow-Up Questions
What are HUTCHMED (China) Limited's key financial statements?
According to the latest financial statement (Form-10K), HUTCHMED (China) Limited has a total asset of $1,753, Net profit of $456
What are the key financial ratios for HMDCF?
HUTCHMED (China) Limited's Current ratio is 3.4, has a Net margin is 83.21, sales per share of $0.62.
How is HUTCHMED (China) Limited's revenue broken down by segment or geography?
HUTCHMED (China) Limited largest revenue segment is Oncology/Immunology - Marketed Products, at a revenue of 2,118,769,307 in the most earnings release.For geography, China is the primary market for HUTCHMED (China) Limited, at a revenue of 3,530,161,153.
Is HUTCHMED (China) Limited profitable?
yes, according to the latest financial statements, HUTCHMED (China) Limited has a net profit of $456
Does HUTCHMED (China) Limited have any liabilities?
yes, HUTCHMED (China) Limited has liability of 515
How many outstanding shares for HUTCHMED (China) Limited?
HUTCHMED (China) Limited has a total outstanding shares of 872.32